Company Performance and Revenue Forecast - Eli Lilly lowered its 2024 full-year revenue forecast, leading to a sharp decline in its stock price [1] - Sales of flagship weight-loss drugs Mounjaro and Zepbound grew slower than expected in Q4 2023, despite anticipated acceleration in H1 2024 [1] - The company reported Q3 2023 sales of these drugs below Wall Street's expectations, raising concerns about moderating demand [4] Stock Price Analysis and Technical Levels - Eli Lilly shares climbed 32% in 2023 but have slumped more than 16% since October 2023 [4] - Key support levels to watch are around $720 and $625, with potential entry points near these levels [5] - Important overhead resistance areas to monitor are near $860 and $965, with potential selling pressure in these regions [3][6] - The stock staged a decisive breakdown below the lower trendline of a symmetrical triangle and the 50-day MA, indicating further short-term downside potential [8][10] Market Sentiment and Trading Volume - The breakdown below the symmetrical triangle occurred on the highest trading volume day in more than two months, signaling strong selling conviction [8] - The stock could remain under scrutiny following the lowered revenue forecast and concerns about demand for its weight-loss drugs [10]

Key TakeawaysGE Vernova shares surged Tuesday after Bank of America analysts raised their price target for the energy company's stock.The analysts suggested the company could benefit from rising prices for gas turbines. GE Vernova is set to report fourth-quarter results on Jan. 22. GE Vernova (GEV) shares jumped Tuesday after Bank of America analysts raised their price target for the company's stock ahead of its fourth-quarter earnings report next week.  The analysts raised their price target to $415 from $ ...

Executive Changes at JPMorgan Chase - JPMorgan Chase announced significant executive role changes, raising questions about the potential successor to CEO Jamie Dimon [2][4] - Jennifer Piepszak, co-CEO of the Commercial and Investment Bank, will transition to the role of Chief Operating Officer (COO) after expressing her preference not to be considered for the CEO position [3][4] - Daniel Pinto, the current COO, will step down from his role at the end of June [3] - Doug Petno, co-head of Global Banking, will succeed Piepszak as co-CEO of the Commercial and Investment Bank alongside Troy Rohrbaugh [5] - John Simmons, head of Commercial Banking, will succeed Doug Petno in his current role [5] Market Performance and Earnings - JPMorgan Chase shares rose 1.3% to $247.47 on Tuesday, reflecting a 47% gain over the past 12 months [4] - The executive changes were announced ahead of the bank's fourth-quarter earnings report, scheduled for Wednesday [4][5] Potential CEO Successors - The executive reshuffle has shifted focus to Doug Petno, Troy Rohrbaugh, and Marianne Lake, CEO of Consumer and Community Banking, as potential candidates to succeed Jamie Dimon [5] - Jennifer Piepszak has expressed her preference for a senior operating role, working closely with Dimon and supporting the leadership team, rather than pursuing the CEO position [6]

Revenue Forecast and Performance - Eli Lilly lowered its revenue forecast for the 2024 fiscal year, expecting full-year revenue of $45 billion, below the previously projected range of $45.4 billion to $46 billion [2][3] - Fourth-quarter revenue is expected to be approximately $13.5 billion, missing analysts' estimates of $13.97 billion [3] - The company's shares dropped nearly 7% to $746 in intraday trading following the announcement, despite a 17% gain over the past 12 months [6] Weight-Loss Drug Sales and Production - Sales of weight-loss drugs Mounjaro and Zepbound grew slower than expected in the fourth quarter, partly due to lower-than-expected inventory [2] - The company anticipates producing at least 60% more salable doses of these drugs in the first half of 2025 compared to 2024 [4][6] Future Outlook - Eli Lilly expects fiscal 2025 revenue to be between $58 billion and $61 billion, slightly above analysts' current projection of $59.33 billion [5] - The company plans to report fourth-quarter earnings and provide a full forecast for fiscal 2025 on February 6 [5]

Boeing's Performance and Challenges - Boeing was the worst-performing stock in the Dow Jones Industrial Average on Tuesday due to declining plane deliveries [2][5] - Boeing delivered 57 commercial planes in Q4 2024, down from 157 a year ago, and 348 for the full year, down from 528 [2] - Airbus delivered 269 planes in Q4 2024 and 766 for the full year, its highest since 2019, widening the gap with Boeing [2] Impact of Labor Dispute - Boeing's Q4 production was impacted by a nearly two-month strike by union machinists, resolved in November with a new contract agreement [3] Safety and Operational Setbacks - Boeing is still recovering from the Alaska Airlines incident in January 2023, where a 737 MAX plane had a door panel detach midair [4] - The FAA stated that Boeing's safety turnaround plan is "not a one-year project" [4] - In December 2023, a 737-800 operated by Jeju Air crashed, killing 179 people, adding to Boeing's challenges [4] Stock Performance - Boeing's shares slid 3% intraday and have lost nearly a quarter of their value over the past year [5] - The company is set to report its Q4 results on January 28 [5]

Key TakeawaysGoogle's search and advertising businesses are the subject of a new investigation from United Kingdom regulators.The regulators will probe whether Google's dominant position in those markets help or hurt consumers.The UK adopted new, stricter antitrust rules at the start of 2025, joining the U.S. and Europe in challenging the biggest tech companies. Regulators in the United Kingdom have opened an investigation into the market position of the search and advertising services of Alphabet's (GOOGL) ...

Earnings and Analyst Sentiment - UnitedHealth Group is set to report fourth-quarter earnings before the market opens Thursday [1][3] - All 17 analysts tracked by Visible Alpha have a "buy" or equivalent rating on the company [1][3] - The consensus price target is nearly $642, representing an 18% premium to UnitedHealth's Monday close around $541 [1] - The consensus price target suggests a close to 10% rise in the shares is expected [3] Financial Performance and Outlook - Wall Street expects the company to report fourth-quarter revenue of $101.68 billion, up 8% year-over-year [2] - Fourth-quarter earnings are expected to be $5.84 billion, or $6.30 per share, compared to $5.46 billion, or $5.83 per share, a year earlier [2] - The company shared its financial outlook for 2025, forecasting revenue of $450 billion to $455 billion and adjusted net income of $29.50 per share to $30 per share [2] Recent Events and Market Reaction - The results will be the company's first quarterly report since the CEO of its UnitedHealthcare unit, Brian Thompson, was fatally shot on Dec. 4 [3] - The company's shares have fallen more than 10% in the weeks since the incident [3] - UnitedHealth shares rose nearly 4% on Monday as broader markets finished mixed [3]

Key TakeawaysBank of America is set to report fourth-quarter earnings before the opening bell Thursday.The bank is expected to post higher revenue and profits from the same time last year.The results come after Bank of America beat estimates in the first three quarters of 2024 as its wealth management and investment banking divisions grew. Bank of America (BAC) is scheduled to post its fourth-quarter earnings report before the opening bell Thursday, with analysts expecting rising revenue and profits. Analys ...

Key TakeawaysTech stocks declined in intraday trading Monday, including every member of the Magnificent 7 except Tesla.Nvidia's stock dropped even as the company announced a series of AI healthcare partnerships.Recent comments from Meta CEO Mark Zuckerberg and Nvidia CEO Jensen Huang have sent quantum computing stocks reeling. Technology stocks struggled across the board in intraday trading Monday, including declines among Magnificent 7 firms and a big hit to quantum computing stocks. The S&P 500 technology ...

Earnings and Market Performance - TSMC shares are expected to remain in focus ahead of the Q4 earnings report, with AI-driven demand anticipated to boost results [1][10] - Analysts predict a quarterly profit of $11.4 billion, driven by strong demand for advanced silicon used in AI infrastructure [4] - TSMC reported a 34% increase in 2024 sales, setting high investor expectations [4] - The stock gained 80% in 2024 and traded 5% higher year-to-date through Friday's close, but fell 3.5% on Monday amid a broader chip stock decline [5] Technical Analysis and Price Levels - TSMC's stock broke out from an 11-week ascending triangle earlier this month but has since retraced to retest the pattern's top trendline [2][10] - The Relative Strength Index (RSI) remains above 50, indicating bullish momentum [2] - A bullish price target of $246 is projected using the measured move technique, representing an 18% increase from Friday's close [8] - Key support levels to monitor include $190 and $175, with potential buying interest near these levels [9][10][11] Industry and Company Outlook - TSMC's outlook and capital expenditure (CapEx) will be closely watched as the company invests billions in new factories amid potential export curbs and tariffs under the incoming Trump administration [5]